• In recent days, Hims & Hers Health launched a consumer campaign promoting peptide therapies just as the FDA intensified scrutiny of several popular peptides over contamination risks and limited human evidence, ahead of an advisory committee meeting.
• This timing highlights a tension between the company’s push into new wellness categories and rising regulatory attention that could influence how its latest offerings are received by clinicians, regulators and consumers.
• Next, we’ll examine how this heightened FDA focus on peptide safety could reshape Hims & Hers Health’s broader investment narrative and growth ambitions.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers Health, you need to believe in its telehealth platform becoming a long term consumer health brand, supported by expanding categories like weight management and sexual health. Right now, the key near term catalyst is execution on its fast growing subscription base, while the biggest risk is mounting regulatory focus on higher profile treatments such as GLP 1s and peptides. The recent peptide scrutiny fits directly into that risk but does not yet redefine the entire story.

Among recent announcements, the upcoming Q2 2026 earnings release on August 10 stands out, as it will update how newer offerings, including weight management and other wellness products, are contributing to revenue and margins. Against a backdrop of FDA attention on peptides, this earnings call may also give investors more clarity on how management is balancing new treatment launches with safety, compliance, and long term brand trust.

Yet behind the platform’s growth, increasing FDA attention on peptides and compounded treatments raises questions investors should understand before assuming that...

Hims & Hers Health's narrative projects $3.8 billion revenue and $164.3 million earnings by 2029.

Uncover how Hims & Hers Health's forecasts yield a $26.82 fair value, a 24% downside to its current price.

Exploring Other Perspectives

Optimistic analysts once projected Hims & Hers revenue reaching about US$5.9 billion by 2029, but the peptide scrutiny and broader regulatory risk you see today might prompt those bulls to rethink how quickly that kind of growth can actually materialize.

Explore 33 other fair value estimates on Hims & Hers Health - why the stock might be worth over 4x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.